Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

The assumptions that the Company used to determine the grant-date fair value of options granted were as follows:

A summary of the Company's stock option activity and related information for the year ended December 31, 2025 is as follows:


(in thousands, except share and per share data)	Options			Weighted Average Exercise Price		Weighted Average Remaining Life (in years)		Aggregate Intrinsic Value
Outstanding January 1, 2025		8,681,473		$	19.47		7.3	$	61,021
Granted		3,783,318			11.66
Exercised		(990,926	)		8.07
Forfeitures		(1,562,822	)		17.62
Outstanding December 31, 2025		9,911,043		$	17.92		8.2	$	52,782
Options exercisable— December 31, 2025		3,621,514		$	17.97		6.7	$	18,627
Options vested or expected to vest— December 31, 2025		9,911,043		$	17.92		8.2	$	52,782

A summary of the Company’s RSU activity and related information for the year ended December 31, 2025 is as follows:


	Number of Shares Underlying RSUs			Weighted Average Grant Date Fair Value
Issued and unvested as of January 1, 2025		3,722,024		$	20.49
Granted		760,367			12.35
Vested		(1,274,489	)		17.86
Forfeited		(769,586	)		17.68
Issued and unvested as of December 31, 2025		2,438,316		$	20.21

The Company recorded stock-based compensation expense in the following expense categories of its statements of operations:

Dyne Therapeutics, Inc. 10-K